Novavax, Inc. logo NVAX - Novavax, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 17
HOLD 3
SELL 3
STRONG
SELL
0
| PRICE TARGET: $18.00 DETAILS
HIGH: $25.00
LOW: $11.00
MEDIAN: $18.00
CONSENSUS: $18.00
UPSIDE: 95.44%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

High-Growth Software 80% confidence

Primary model: Revenue × Terminal Margin DCF

Valuation Signal Undervalued Strong
Trading 86.9% below fair value
Current Price $9.21
Bear Case $28.91 213.9% upside ($28.91 - $9.21) / $9.21 = 213.9% 18% rev growth, 21% terminal margin
Fair Value $70.37 664.1% upside ($70.37 - $9.21) / $9.21 = 664.1% 30% rev growth, 28% terminal margin
Bull Case $103.73 1026.3% upside ($103.73 - $9.21) / $9.21 = 1026.3% 35% rev growth, 32% terminal margin

Adjust Assumptions

30.0%
28.0%
12.0%

Key Value Driver

Revenue growth (30%) × margin expansion to 28%

Terminal Value % of EV 69%
Implied Market Multiple 0.9x

Plain-Language Summary

Projecting 30% revenue growth with FCF margins expanding from 0% to 28% over 10 years, discounted at 12%, the base-case value is $70.37 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (23 analysts) $18.00
Analyst Range $11.00 – $25.00
Divergence from AlphaVal 291%

Warnings

Our estimate assumes profit margins grow from 0% to 28% over 10 years. If that improvement stalls, the company is worth considerably less.
Gross margin of 94% means each dollar of revenue is highly profitable. As the company grows, overhead costs should shrink as a share of revenue, boosting overall profits.
Wall Street's average price target is $18.00 (from 23 analysts). Our estimate is 291% above the consensus -- consider that gap carefully.

Key Risks

  • Current FCF misleads — the model values future margins, not today's cash
  • SBC dilution is the hidden tax: 2-4% annual share growth compounds fast
  • Revenue deceleration is inevitable — the question is when and how steep